Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

NCT03280563
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat, Exemestane, Fulvestrant, Ipatasertib, Tamoxifen, Abemaciclib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 21, 2026, 9:06 AM EDT
Terminated Phase 1 Interventional

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

NCT05511844
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 Gene Mutation
Interventions
ORM-5029
Drug
Lead sponsor
Orum Therapeutics USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Oct 21, 2026, 9:06 AM EDT
Completed No phase listed Observational

Decisions of Young Women With Breast Cancer Regarding Fertility Preservation Before Cancer Treatment and Family Building After Treatment

NCT03817814
View directory record Official record
Conditions
Fertility Preservation, Breast Cancer
Interventions
web-based questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients

NCT00001504
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
9-cis-Retinoic Acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 9:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

NCT03366844
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, RT Boost
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

NCT03471663
View directory record Official record
Conditions
Breast Cancer
Interventions
D-0502, palbociclib
Drug
Lead sponsor
InventisBio Co., Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
11
States / cities
Fresno, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 21, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer

NCT00925652
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, Cyclophosphamide, Methotrexate, Lifestyle: Diet, Lifestyle: Diet+Exercise
Drug · Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Bexarotene in Treating Patients With Metastatic Breast Cancer

NCT00003752
View directory record Official record
Conditions
Breast Cancer
Interventions
bexarotene
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 21, 2026, 9:06 AM EDT
Active, not recruiting Not applicable Interventional

Telehealth Weight Loss Program for Breast Cancer Survivors

NCT04855552
View directory record Official record
Conditions
Cancer Survivors, Cancer of Breast, Body Weight, Overweight and Obesity
Interventions
Behavioral Weight-loss Program Via Telehealth, Behavioral Weight-Loss Program Via Telehealth - Weight Measures, Validated Surveys of Patient-Reported Outcomes
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
Interventions
citalopram hydrobromide, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
198
States / cities
Augusta, Georgia • Aurora, Illinois • Bloomington, Illinois + 126 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Results available

Autologous Vaccination With Lethally Irradiated, Autologous Breast Cancer Cells Engineered to Secrete GM-CSF in Women With Operable Breast Cancer

NCT00880464
View directory record Official record
Conditions
Breast Cancer
Interventions
Autologous, Lethally Irradiated Breast Cancer Cells
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

NCT03107663
View directory record Official record
Conditions
Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
Interventions
⁸⁹Zr-Df-IAB22M2C Infusion
Drug
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

NCT00003199
View directory record Official record
Conditions
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
19 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 21, 2026, 9:06 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

NCT04333706
View directory record Official record
Conditions
Breast, Metastatic, Triple Negative, Cancer, Disseminated Tumor Cell
Interventions
Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine
Drug · Combination Product
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

NCT01919749
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
treated recommended
Other
Lead sponsor
Translational Drug Development
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 21, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer

NCT02777164
View directory record Official record
Conditions
Breast Cancer
Interventions
MIRA device imaging
Device
Lead sponsor
Real Imaging Ltd.
Industry
Eligibility
30 Years to 70 Years · Female only
Enrollment
740 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated May 3, 2019 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

NCT00574587
View directory record Official record
Conditions
Breast Cancer
Interventions
Vorinostat, Paclitaxel, Trastuzumab, Doxorubicin, Cyclophosphamide, Surgery
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 21, 2026, 9:06 AM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 21, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Results available

Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer

NCT03648983
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
arm circumference measurement, Bioimpedance spectroscopy
Procedure · Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers

NCT03573661
View directory record Official record
Conditions
Palpable Breast Cancer
Interventions
Breast Cancer Locator (BCL)
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Burlington, Massachusetts • Keene, New Hampshire • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 21, 2026, 9:06 AM EDT
Completed Not applicable Interventional

Patient Navigator Project

NCT00375024
View directory record Official record
Conditions
Breast Cancer, Colon Cancer
Interventions
Patient Navigation, Clinic Staff
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1,267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 21, 2026, 9:06 AM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 21, 2026, 9:06 AM EDT